Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical & Experimental Metastasis
Published in: Clinical & Experimental Metastasis 5-6/2018

01-08-2018 | Research Paper

Alternative splicing and cancer metastasis: prognostic and therapeutic applications

Authors: Diego M. Marzese, Ayla O. Manughian-Peter, Javier I. J. Orozco, Dave S. B. Hoon

Published in: Clinical & Experimental Metastasis | Issue 5-6/2018

Login to get access

Abstract

Metastatic cells exhibit an extraordinary phenotypic plasticity, not only in adapting to unfamiliar microenvironments but also in surviving aggressive treatments and immune responses. A major source of phenotypic variability is alternative splicing (AS) of the pre-messenger RNA. This process is catalyzed by one of the most complex pieces of cellular molecular regulatory events, the spliceosome, which is composed of ribonucleoproteins and polypeptides termed spliceosome factors. With strong evidence indicating that AS affects nearly all genes encoded by the human genome, aberrant AS programs have a significant impact on cancer cell development and progression. In this review, we present insights about the genomic and epigenomic factors affecting AS, summarize the most recent findings linking aberrant AS to metastatic progression, and highlight potential prognostic and therapeutic applications.
Literature
1.
Feinberg AP, Koldobskiy MA, Gondor A (2016) Epigenetic modulators, modifiers and mediators in cancer aetiology and progression. Nat Rev Genet 17(5):284–299PubMedPubMedCentralCrossRef
2.
3.
4.
Ghigna C et al (2010) Pro-metastatic splicing of Ron proto-oncogene mRNA can be reversed: therapeutic potential of bifunctional oligonucleotides and indole derivatives. RNA Biol 7(4):495–503PubMedCrossRef
5.
Tang JY et al (2013) Alternative splicing for diseases, cancers, drugs, and databases. Sci World J 2013:703568
6.
Koo T, Wood MJ (2013) Clinical trials using antisense oligonucleotides in duchenne muscular dystrophy. Hum Gene Ther 24(5):479–488PubMedCrossRef
7.
Faravelli I et al (2015) Spinal muscular atrophy-recent therapeutic advances for an old challenge. Nat Rev Neurol 11(6):351–359PubMedCrossRef
8.
Bonnal S, Vigevani L, Valcarcel J (2012) The spliceosome as a target of novel antitumour drugs. Nat Rev Drug Discov 11(11):847–859PubMedCrossRef
9.
10.
11.
Zhang J, Manley JL (2013) Misregulation of pre-mRNA alternative splicing in cancer. Cancer Discov 3(11):1228–1237PubMedCrossRef
12.
13.
DeBoever C et al (2015) Transcriptome sequencing reveals potential mechanism of cryptic 3′ splice site selection in SF3B1-mutated cancers. PLoS Comput Biol 11(3):e1004105PubMedPubMedCentralCrossRef
14.
15.
16.
17.
Okeyo-Owuor T et al (2015) U2AF1 mutations alter sequence specificity of pre-mRNA binding and splicing. Leukemia 29(4):909–917PubMedCrossRef
18.
19.
Zhang J et al (2015) Disease-associated mutation in SRSF2 misregulates splicing by altering RNA-binding affinities. Proc Natl Acad Sci USA 112(34):4726–4734CrossRef
20.
21.
22.
Lev Maor G, Yearim A, Ast G (2015) The alternative role of DNA methylation in splicing regulation. Trends Genet 31(5):274–280PubMedCrossRef
23.
Zhou HL et al (2014) Regulation of alternative splicing by local histone modifications: potential roles for RNA-guided mechanisms. Nucleic Acids Res 42(2):701–713PubMedCrossRef
24.
25.
Wong JJ et al (2014) Epigenetic modifications of splicing factor genes in myelodysplastic syndromes and acute myeloid leukemia. Cancer Sci 105(11):1457–1463PubMedPubMedCentralCrossRef
26.
Marzese DM et al (2015) Brain metastasis is predetermined in early stages of cutaneous melanoma by CD44v6 expression through epigenetic regulation of the spliceosome. Pigment Cell Melanoma Res 28(1):82–93PubMedCrossRef
27.
Maunakea AK et al (2013) Intragenic DNA methylation modulates alternative splicing by recruiting MeCP2 to promote exon recognition. Cell Res 23(11):1256–1269PubMedPubMedCentralCrossRef
28.
Saint-Andre V et al (2011) Histone H3 lysine 9 trimethylation and HP1gamma favor inclusion of alternative exons. Nat Struct Mol Biol 18(3):337–344PubMedCrossRef
29.
Warzecha CC, Carstens RP (2012) Complex changes in alternative pre-mRNA splicing play a central role in the epithelial-to-mesenchymal transition (EMT). Semin Cancer Biol 22(5–6):417–427PubMedPubMedCentralCrossRef
30.
31.
32.
Zhang P et al (2013) Exon 4 deletion variant of epidermal growth factor receptor enhances invasiveness and cisplatin resistance in epithelial ovarian cancer. Carcinogenesis 34(11):2639–2646PubMedCrossRef
33.
Solomon H, Sharon M, Rotter V (2014) Modulation of alternative splicing contributes to cancer development: focusing on p53 isoforms, p53beta and p53gamma. Cell Death Differ 21(9):1347–1349PubMedPubMedCentralCrossRef
34.
Avery-Kiejda KA et al (2014) The relative mRNA expression of p53 isoforms in breast cancer is associated with clinical features and outcome. Carcinogenesis 35(3):586–596CrossRefPubMed
35.
Jin W et al (2000) Fibroblast growth factor receptor-1 alpha-exon exclusion and polypyrimidine tract-binding protein in glioblastoma multiforme tumors. Cancer Res 60(5):1221–1224PubMed
36.
He X et al (2014) Involvement of polypyrimidine tract-binding protein (PTBP1) in maintaining breast cancer cell growth and malignant properties. Oncogenesis 3:e84PubMedPubMedCentralCrossRef
37.
He X et al (2007) Knockdown of polypyrimidine tract-binding protein suppresses ovarian tumor cell growth and invasiveness in vitro. Oncogene 26(34):4961–4968PubMedPubMedCentralCrossRef
38.
39.
Silipo M, Gautrey H, Tyson-Capper A (2015) Deregulation of splicing factors and breast cancer development. J Mol Cell Biol 7(5):388–401PubMedCrossRef
40.
41.
42.
43.
44.
45.
Ghigna C et al (2005) Cell motility is controlled by SF2/ASF through alternative splicing of the Ron protooncogene. Mol Cell 20(6):881–890PubMedCrossRef
46.
47.
Ben-Hur V et al (2013) S6K1 alternative splicing modulates its oncogenic activity and regulates mTORC1. Cell Rep 3(1):103–115PubMedCrossRef
48.
Ishii H et al (2014) Epithelial splicing regulatory proteins 1 (ESRP1) and 2 (ESRP2) suppress cancer cell motility via different mechanisms. J Biol Chem 289(40):27386–27399PubMedPubMedCentralCrossRef
49.
Yae T et al (2012) Alternative splicing of CD44 mRNA by ESRP1 enhances lung colonization of metastatic cancer cell. Nat Commun 3:883CrossRefPubMed
50.
Chen L et al (2017) Snail driving alternative splicing of CD44 by ESRP1 enhances invasion and migration in epithelial ovarian cancer. Cell Physiol Biochem 43(6):2489–2504PubMedCrossRef
51.
52.
Ryan MC et al (2012) SpliceSeq: a resource for analysis and visualization of RNA-Seq data on alternative splicing and its functional impacts. Bioinformatics 28(18):2385–2387PubMedPubMedCentralCrossRef
53.
54.
Darman RB et al (2015) Cancer-associated SF3B1 hotspot mutations induce cryptic 3′ splice site selection through use of a different branch point. Cell Rep 13(5):1033–1045PubMedCrossRef
55.
56.
57.
Martin M et al (2013) Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3. Nat Genet 45(8):933–936PubMedPubMedCentralCrossRef
58.
Quesada V et al (2011) Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat Genet 44(1):47–52PubMedCrossRef
59.
Kaida D et al (2007) Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA. Nat Chem Biol 3(9):576–583PubMedCrossRef
60.
Kotake Y et al (2007) Splicing factor SF3b as a target of the antitumor natural product pladienolide. Nat Chem Biol 3(9):570–575PubMedCrossRef
61.
Hasegawa M et al (2011) Identification of SAP155 as the target of GEX1A (herboxidiene), an antitumor natural product. ACS Chem Biol 6(3):229–233PubMedCrossRef
62.
Graveley BR, Maniatis T (1998) Arginine/serine-rich domains of SR proteins can function as activators of pre-mRNA splicing. Mol Cell 1(5):765–771PubMedCrossRef
63.
64.
Twyffels L, Gueydan C, Kruys V (2011) Shuttling SR proteins: more than splicing factors. FEBS J 278(18):3246–3255PubMedCrossRef
65.
Long JC, Caceres JF (2009) The SR protein family of splicing factors: master regulators of gene expression. Biochem J 417(1):15–27CrossRefPubMed
66.
Araki S et al (2015) Inhibitors of CLK protein kinases suppress cell growth and induce apoptosis by modulating pre-mRNA splicing. PLoS ONE 10(1):e0116929PubMedPubMedCentralCrossRef
67.
68.
Ohe K, Hagiwara M (2015) Modulation of alternative splicing with chemical compounds in new therapeutics for human diseases. ACS Chem Biol 10(4):914–924PubMedCrossRef
69.
70.
71.
Dewaele M et al (2016) Antisense oligonucleotide-mediated MDM4 exon 6 skipping impairs tumor growth. J Clin Invest 126(1):68–84PubMedCrossRef
72.
Castanotto D, Stein CA (2014) Antisense oligonucleotides in cancer. Curr Opin Oncol 26(6):584–589PubMedCrossRef
73.
74.
75.
Bengtsson NE et al (2017) Muscle-specific CRISPR/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy. Nat Commun 8:14454PubMedPubMedCentralCrossRef
76.
Nguyen TH, Anegon I (2016) Successful correction of hemophilia by CRISPR/Cas9 genome editing in vivo: delivery vector and immune responses are the key to success. EMBO Mol Med 8(5):439–441PubMedPubMedCentralCrossRef
77.
Feng Y et al (2015) Targeting CDK11 in osteosarcoma cells using the CRISPR-Cas9 system. J Orthop Res 33(2):199–207PubMedCrossRef
78.
Liao Y et al (2017) Targeting programmed cell death ligand 1 by CRISPR/Cas9 in osteosarcoma cells. Oncotarget 8(18):30276–30287PubMedPubMedCentral
79.
80.
81.
Zhou Q et al (2015) A chemical genetics approach for the functional assessment of novel cancer genes. Cancer Res 75(10):1949–1958PubMedCrossRef
82.
Bustos M et al (2018) Abstract P1-05-02: CRISPR/Cas9-guided editing of spliceosome factors enhances major histocompatibility complex proteins in triple-negative breast cancer. Can Res 78(4 Supplement):P1-05-02CrossRef
83.
Eskens FA et al (2013) Phase I pharmacokinetic and pharmacodynamic study of the first-in-class spliceosome inhibitor E7107 in patients with advanced solid tumors. Clin Cancer Res 19(22):6296–6304PubMedCrossRef
84.
Hong DS et al (2014) A phase I, open-label, single-arm, dose-escalation study of E7107, a precursor messenger ribonucleic acid (pre-mRNA) splicesome inhibitor administered intravenously on days 1 and 8 every 21 days to patients with solid tumors. Invest New Drugs 32(3):436–444PubMedCrossRef
85.
Seiler M et al (2018) H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers. Nat Med 24(4):497–504PubMedCrossRefPubMedCentral
86.
Bedikian AY et al (2006) Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma study group. J Clin Oncol 24(29):4738–4745PubMedCrossRef
87.
O’Brien S et al (2007) Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol 25(9):1114–1120PubMedCrossRef
88.
Chanan-Khan AA et al (2009) Phase III randomised study of dexamethasone with or without oblimersen sodium for patients with advanced multiple myeloma. Leuk Lymphoma 50(4):559–565PubMedCrossRef
89.
Chi KN et al (2010) Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 28(27):4247–4254PubMedCrossRef
90.
Beer TM et al (2017) Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial. Lancet Oncol 18(11):1532–1542PubMedCrossRef
91.
Chi KN et al (2017) Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial. Lancet Oncol 18(4):473–485PubMedCrossRef
Metadata
Title
Alternative splicing and cancer metastasis: prognostic and therapeutic applications
Authors
Diego M. Marzese
Ayla O. Manughian-Peter
Javier I. J. Orozco
Dave S. B. Hoon
Publication date
01-08-2018
Publisher
Springer Netherlands
Published in
Clinical & Experimental Metastasis / Issue 5-6/2018
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-018-9905-y

Other articles of this Issue 5-6/2018

Clinical & Experimental Metastasis 5-6/2018 Go to the issue

Research Paper

Genetics of metastasis: melanoma and other cancers

Research Paper

Update on systemic therapy for advanced cutaneous melanoma and recent development of novel drugs

Research Paper

Lymphedema surgery: the current state of the art

Review

Cancer initiation and progression within the cancer microenvironment

Commentary

Future perspectives: cancer metastases

Review

Update on the indications and results of sentinel node mapping in upper GI cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits